Zobrazeno 1 - 10
of 6 262
pro vyhledávání: '"ER /HER2−"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zhi-Ming Shao, Li Cai, Shusen Wang, Xichun Hu, Kunwei Shen, Haibo Wang, Huiping Li, Jifeng Feng, Qiang Liu, Jing Cheng, Xinhong Wu, Xiaojia Wang, Hongyuan Li, Ting Luo, Jinping Liu, Khalid Amin, Khemaies Slimane, Yongping Qiao, Yongmin Liu, Zhongsheng Tong
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated t
Externí odkaz:
https://doaj.org/article/54f05c5481a746a1854d62942484ed79
Autor:
Goldvaser H; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1101 Hempstead Turnpike, Uniondale, NY, 11553, USA. hadar7g@gmail.com., Yerushalmi R; Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel., Mutai R; Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel., Kuchuk I; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.; The Oncology Institute, Meir Medical Center, Tel-Aviv University, Kfar Saba, Israel., Toker M; Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Medicine, Ben Gurion University, Beer Sheva, Israel., Paluch-Shimon S; Hadassah University Hospital, Jerusalem, Israel.; Faculty of Medicine, the Hebrew University, Jerusalem, Israel Jerusalem, Israel., Drumea K; Lin Medical Center, Haifa, Israel.; Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel., Evron E; Faculty of Medicine, the Hebrew University, Jerusalem, Israel Jerusalem, Israel.; Kaplan Medical Center, Rehovot, Israel., Sonnenblick A; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.; Sourasky Medical Center, Tel Aviv, Israel., Gal-Yam E; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.; Sheba Medical Center, Ramat Gan, Israel., Sela GB; Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.; Emek Medical Center, Afula, Israel., Shai A; Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.; Rambam Health Care Campus, Haifa, Israel., Merose R; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.; Shamir Medical Center, Rishon LeZion, Israel., Bareket-Samish A; BioInsight Ltd, Binyamina, Israel., Soussan-Gutman L; Oncotest-Rhenium, Modi'in, Israel., Stemmer SM; Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mukohara T; National Cancer Center Hospital East, Kashiwa, Japan., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Sommerhalder D; NEXT Oncology, San Antonio, TX, USA., Yonemori K; National Cancer Center Hospital, Tokyo, Japan., Hamilton E; Sarah Cannon Research Institute, Nashville, TN, USA., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim JH; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Iwata H; Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan., Yamashita T; Kanagawa Cancer Center, Yokohama, Japan., Layman RM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mita M; Hoag Family Cancer Institute, Newport Beach, CA, USA., Clay T; Saint John of God Subiaco Hospital, Perth, Western Australia, Australia., Chae YS; Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Oakman C; Western Health, Sunshine Hospital, St Albans, Victoria, Australia., Yan F; Swedish Cancer Institute, First Hill-True Family Women's Cancer Center, Seattle, WA, USA., Kim GM; Yonsei University College of Medicine, Seoul, Republic of Korea., Im SA; Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea., Lindeman GJ; Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Rugo HS; University of California, San Francisco, CA, USA., Liyanage M; Pfizer, San Diego, CA, USA., Saul M; Pfizer, San Diego, CA, USA., Le Corre C; Pfizer, San Diego, CA, USA., Skoura A; Pfizer, Collegeville, PA, USA., Liu L; Pfizer, San Diego, CA, USA., Li M; Pfizer, San Francisco, CA, USA. meng.li7@pfizer.com., LoRusso PM; Yale School of Medicine, New Haven, CT, USA. patricia.lorusso@yale.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2242-2250. Date of Electronic Publication: 2024 Jun 01.
Autor:
Mukohara T; National Cancer Center Hospital East, Kashiwa, Japan., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Sommerhalder D; NEXT Oncology, San Antonio, TX, USA., Yonemori K; National Cancer Center Hospital, Tokyo, Japan., Hamilton E; Sarah Cannon Research Institute, Nashville, TN, USA., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim JH; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Iwata H; Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan., Yamashita T; Kanagawa Cancer Center, Yokohama, Japan., Layman RM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mita M; Hoag Family Cancer Institute, Newport Beach, CA, USA., Clay T; Saint John of God Subiaco Hospital, Perth, Western Australia, Australia., Chae YS; Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Oakman C; Western Health, Sunshine Hospital, St Albans, Victoria, Australia., Yan F; Swedish Cancer Institute, First Hill-True Family Women's Cancer Center, Seattle, WA, USA., Kim GM; Yonsei University College of Medicine, Seoul, Republic of Korea., Im SA; Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea., Lindeman GJ; Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Rugo HS; University of California, San Francisco, CA, USA., Liyanage M; Pfizer, San Diego, CA, USA., Saul M; Pfizer, San Diego, CA, USA., Le Corre C; Pfizer, San Diego, CA, USA., Skoura A; Pfizer, Collegeville, PA, USA., Liu L; Pfizer, San Diego, CA, USA., Li M; Pfizer, San Francisco, CA, USA. meng.li7@pfizer.com., LoRusso PM; Yale School of Medicine, New Haven, CT, USA. patricia.lorusso@yale.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2371.
Autor:
Haricharan BV, Shilpa Karamchedu, Rasheed Fatima, Shaik Nazeer, Fatima ., Sagarika D, Suresh K, Florence Nightingale
Publikováno v:
Journal of Clinical and Basic Research, Vol 7, Iss 3, Pp 12-14 (2023)
Background: Using molecular biomarkers of breast cancer (BC) receives optimal treatment. Established biomarkers like estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 may play significant roles in the sub-categorization of BC to pred
Externí odkaz:
https://doaj.org/article/04a2f54b88fb486eb3d9a04503b0f09e
Autor:
Bagadi, Venkata Hari Charan1, Karamchedu, Shilpa1 dr.kshilpa@rediffmail.com, Fatima, Rasheed1, Nazeer, Shaik1, Fatima1, Devunoori, Sagarika1, Karamchedu, Suresh1, Nightingale, Florence1
Publikováno v:
Journal of Clinical & Basic Research. 2023, Vol. 7 Issue 3, p12-14. 3p.
Autor:
Bruss C; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Albert V; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Seitz S; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Blaimer S; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Kellner K; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Pohl F; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.; Department of Radiotherapy, University Medical Center Regensburg, Regensburg, Germany., Ortmann O; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Brockhoff G; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany., Wege AK; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany.
Publikováno v:
Frontiers in immunology [Front Immunol] 2024 Apr 29; Vol. 15, pp. 1355130. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024).